Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: A multicenter phase 2 study

Yasushi Takamatsu, Kazutaka Sunami, Tsuyoshi Muta, Hiroaki Morimoto, Toshihiro Miyamoto, Masakazu Higuchi, Kimiharu Uozumi, Hiroyuki Hata, Kazuo Tamura

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: A multicenter phase 2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences